Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
Date:8/12/2009

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

    Highlights

    - Start of the preregistration clinical trial with Glybera(R)
      in Canada following two previous clinical trials
    - Presentation of additional data indicating that Glybera(R) offers
      a clinically important health benefit, accomplished by a significant
      and clinically important reduction in the incidence of acute
      pancreatitis in patients
    - Significant progress in research and development for other
      pipeline projects including hemophilia B, Duchenne muscular dystrophy
      and Parkinson's disease
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 25 million at June 30, 2009

Results comparison

AMT's key financial figures are well within the budgets for the first semester and therefore remain in line with the guidance that the company has given for 2009. The operating loss increased to EUR 9.9 million for the six months ended June 30, 2009, from EUR 9.1 million for the same period in 2008. This difference is primarily due to the increase of research & development costs to EUR 7.1 million from EUR 5.8 million in the same period of 2008. This increase is particularly related to the clinical development and regulatory work on the company's lead product, Glybera(R), as well as increased staffing for this and other programs. General and administrative costs decreased to EUR 2.9 million, from EUR 3.3 million in the first half of 2008, primarily as a result of decreased advisor's fees.

The net loss for the half of 2009 was EUR 9.4 million, as compared to a net loss of EUR 8.1 million for the first half of 2008.

At June 30, 2009, AMT's cash and cash equivalents amounted to E
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
11. Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... (OTC Bulletin Board: WDST ) ( www.Regenicin.com ... Christopher A. Hadsall, whose primary responsibilities will be to ... as Chief Operating Officer.  Mr. Hadsall brings 12 years ... instrumental in working with various military groups to build ...
... Texas, Oct. 5 C3i, the leader in technology ... (BMS), a leading global biopharmaceutical company, will deliver a ... the newest version of Oracle Clinical/Remote Data Capture (OCRDC) ... the Oracle Health Sciences User Group conference (OHSUG) in ...
... Technologies, Inc. (ISTO), an  orthobiologics company with a cell-based ... patient enrollment in the Phase I clinical study for ... designed for the treatment of discogenic back pain. The ... All patients enrolled in the trial suffered from persistent ...
Cached Biology Technology:Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3
(Date:4/20/2014)... Stem cells the body,s master cells demonstrate ... level, according to a study published today from scientists ... as auxeticity is one which may have application ... Most materials when stretched will contract. For example, if ... will get thinner. The opposite is also true: squeeze ...
(Date:4/20/2014)... pancreatic cancers also promote drug-resistance and ultimately spur tumor ... School of Medicine have discovered a molecule, or biomarker, ... appears responsible for inducing tumor metastasis by enhancing the ... findings, published in the April 20, 2014 online issue ... new therapeutic opportunities for reversing drug resistance in a ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... key step toward providing patients with treatments based on their ... Genomics Consortium (IGC) have launched a new joint venture that ... Called Paradigm, the new nonprofit company brings together the expertise ... using genetic information to understand and treat disease. Beginning ...
... Aug. 16, 2012 Reportlinker.com announces that ... in its catalogue: Booming ... http://www.reportlinker.com/p0946283/Booming-CCTV-Market-in-Asia-Forecast-to-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... market has been experiencing significant growth due ...
... Aug. 15, 2012 DNA sequencing is rapidly getting faster ... patients will be able to use this information. In ... from around the world are vying to interpret the ... cause remains a mystery—with the goal of establishing "best ...
Cached Biology News:Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics 2Booming CCTV Market in Asia Forecast to 2014 2Booming CCTV Market in Asia Forecast to 2014 3Thirty teams compete to interpret three families' genomes 2Thirty teams compete to interpret three families' genomes 3Thirty teams compete to interpret three families' genomes 4Thirty teams compete to interpret three families' genomes 5
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... Extracts are optimized for maximum packaging efficiencies ... high efficiency extracts (> 109 pfu/g with ... a library containing at least 5 ... extracts are made from a specially designed ...
... Panorama Mouse/Rat Tissue Extract Protein Array Kit ... various tissue extracts. The expression of a ... a protein specific antibody. When the antibody ... by a sensitive chemiluminescent or fluorescent signal ...
... offers pre-validated SNP sequencing ... amplicons within 93 genes ... and more than 80 ... assays were developed and ...
Biology Products: